Form 4: Neurocrine Director Sells Shares Under 10b5-1 Plan

Neurocrine Biosciences Director George J. Morrow exercised options and sold 15,000 shares of common stock for approximately $143.37 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Director George J. Morrow of Neurocrine Biosciences Inc. (NBIX) exercised 15,000 non-qualified stock options at an exercise price of $47.89 per share.
• Concurrently, Morrow sold 15,000 shares of common stock at a weighted average price of $143.3675 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 26, 2025.
• Following these transactions, Morrow beneficially owns 7,068 shares of Neurocrine Biosciences common stock directly.
• The options were granted on May 20, 2016, vested in 12 equal monthly installments beginning June 20, 2016, and were due to expire on May 20, 2026.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a pre-arranged plan, not indicative of positive or negative company performance or outlook.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to stock sales rather than an immediate reaction to market conditions.
• The sale price of $143.3675 per share is significantly higher than the exercise price of $47.89, indicating a substantial gain for the director.

Negatives

• A director selling shares could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The disposition reported was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2025.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical industries. These plans allow executives to sell shares systematically over time, reducing the perception of trading on material non-public information. This specific transaction reflects a director monetizing vested options, a routine event for long-serving executives.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance, providing an affirmative defense against insider trading allegations. Many public company executives across various industries utilize such plans to manage their equity holdings in a pre-scheduled, transparent manner.
• The significant difference between the option exercise price and the sale price is typical for long-held, in-the-money options in successful growth companies like Neurocrine Biosciences.

Stakeholder Impact

• Shareholders: The sale by a director could be viewed as a minor negative, but the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic selling. The director still retains 7,068 shares.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where a director exercised vested stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan. Such transactions are common and generally do not reflect a change in the company's fundamental outlook or the director's confidence in the company. Therefore, it does not provide a basis for altering an existing investment recommendation.

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1, Director Transaction, George J Morrow